Paclitaxel is under clinical development by Fulgent Pharma and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Recurrent Head And Neck Squamous Cell Carcinoma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Paclitaxel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Paclitaxel overview

Paclitaxel (FID-007) is under development for the treatment of non-small cell lung cancer, breast cancer, pancreatic cancer, head and neck cancer, bile duct cancer, recurrent head and neck cancer squamous cell carcinoma, paranasal sinuses and nasal cavity cancer, nasopharyngeal cancer, oropharyngeal cancer, oral cavity cancer, hypopharyngeal cancer and laryngeal cancer. It is administered through intravenous route. The drug candidate acts by targeting tubulin. It is developed based on nanoencapsulation technology. It was also under development for the treatment of leukemia, gastric cancer, ovarian cancer and bladder cancer.

Fulgent Pharma overview

Fulgent Pharma  is a pharmaceutical company focusing on developing and commercializing innovative cancer therapeutics. The company is headquartered in Temple City, California, United States.

For a complete picture of Paclitaxel’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.